Investment Thesis
Bristol Myers Squibb demonstrates solid fundamental health with strong profitability margins (63.8% gross, 14.6% net) and exceptional cash generation (FCF of $12.8B, 26.7% margin). However, revenue stagnation (-0.2% YoY) and elevated leverage (2.43x debt-to-equity) warrant caution, despite manageable interest coverage of 21.9x and strong operational efficiency metrics.
Strengths
- Exceptional free cash flow generation of $12.8B with 26.7% FCF margin indicating robust operational cash conversion
- Strong profitability with gross margin of 63.8% and net margin of 14.6%, reflecting pricing power and cost discipline
- Excellent interest coverage ratio of 21.9x demonstrates comfortable debt servicing capacity despite high absolute debt levels
- High return on equity of 38.2% indicates efficient capital deployment in shareholder value creation
Risks
- Revenue stagnation with flat year-over-year growth (-0.2%) suggests mature portfolio without clear growth catalysts
- Elevated leverage with debt-to-equity ratio of 2.43x and $44.8B long-term debt; vulnerable to rising interest rates
- Modest current ratio of 1.26x indicates tightened short-term liquidity relative to current liabilities
- Pharmaceutical industry exposure to patent expirations, pricing pressures, and regulatory headwinds
Key Metrics to Watch
- Revenue growth trajectory and new product pipeline contribution
- Debt reduction progress and leverage ratio improvement toward healthier 2.0x threshold
- Free cash flow sustainability and maintenance of 25%+ FCF margins
- Operating margin stability amid pricing and cost pressures in pharma sector
Financial Metrics
Revenue
48.2B
Net Income
7.1B
EPS (Diluted)
$3.46
Free Cash Flow
12.8B
Total Assets
90.0B
Cash
10.2B
Profitability Ratios
Gross Margin
63.8%
Operating Margin
19.4%
Net Margin
14.6%
ROE
38.2%
ROA
7.8%
FCF Margin
26.7%
Balance Sheet & Liquidity
Current Ratio
1.26x
Quick Ratio
1.14x
Debt/Equity
2.43x
Debt/Assets
79.4%
Interest Coverage
21.95x
Long-term Debt
44.8B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T03:58:10.738102 |
Data as of: 2025-12-31 |
Powered by Claude AI